Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration

L. G. Feun, R. Gonzalez, N. Savaraj, J. Hanlon, M. Collier, W. A. Robinson, N. J. Clendeninn

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

A phase II trial of piritrexim (2,4-diamino-6[2,5-dimethoxybenzyl]-5-methyl pyrido-[2,3d] pyrimidine, 30IU74; PTX) was conducted for patients with metastatic malignant melanoma using an intermittent, low-dose oral administration schedule. PTX was administered at a starting dose of 25 mg orally three times per day for 5 days weekly for 3 weeks followed by 1 week of rest. Thirty-one patients were entered onto the study. Among 31 patients assessable for response, there were two complete responses (CRs) and five partial responses (PRs) for a response rate (CR plus PR) of 23% (95% confidence limit, 10% to 42%). Five responses occurred in soft tissue lesions, and two responses occurred in lung lesions. The initial dose schedule was well tolerated. The dose-limiting toxicity was myelosuppression. PTX administered in this schedule appears to be active against malignant melanoma. Further clinical trials to confirm these results are underway.

Original languageEnglish
Pages (from-to)464-467
Number of pages4
JournalJournal of Clinical Oncology
Volume9
Issue number3
StatePublished - Dec 1 1991

Fingerprint

Melanoma
Appointments and Schedules
Oral Administration
Clinical Trials
Lung
piritrexim
pyrimidine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Feun, L. G., Gonzalez, R., Savaraj, N., Hanlon, J., Collier, M., Robinson, W. A., & Clendeninn, N. J. (1991). Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. Journal of Clinical Oncology, 9(3), 464-467.

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. / Feun, L. G.; Gonzalez, R.; Savaraj, N.; Hanlon, J.; Collier, M.; Robinson, W. A.; Clendeninn, N. J.

In: Journal of Clinical Oncology, Vol. 9, No. 3, 01.12.1991, p. 464-467.

Research output: Contribution to journalArticle

Feun, LG, Gonzalez, R, Savaraj, N, Hanlon, J, Collier, M, Robinson, WA & Clendeninn, NJ 1991, 'Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration', Journal of Clinical Oncology, vol. 9, no. 3, pp. 464-467.
Feun, L. G. ; Gonzalez, R. ; Savaraj, N. ; Hanlon, J. ; Collier, M. ; Robinson, W. A. ; Clendeninn, N. J. / Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 3. pp. 464-467.
@article{ccc18c8538b04c92a588e0d48ddce190,
title = "Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration",
abstract = "A phase II trial of piritrexim (2,4-diamino-6[2,5-dimethoxybenzyl]-5-methyl pyrido-[2,3d] pyrimidine, 30IU74; PTX) was conducted for patients with metastatic malignant melanoma using an intermittent, low-dose oral administration schedule. PTX was administered at a starting dose of 25 mg orally three times per day for 5 days weekly for 3 weeks followed by 1 week of rest. Thirty-one patients were entered onto the study. Among 31 patients assessable for response, there were two complete responses (CRs) and five partial responses (PRs) for a response rate (CR plus PR) of 23{\%} (95{\%} confidence limit, 10{\%} to 42{\%}). Five responses occurred in soft tissue lesions, and two responses occurred in lung lesions. The initial dose schedule was well tolerated. The dose-limiting toxicity was myelosuppression. PTX administered in this schedule appears to be active against malignant melanoma. Further clinical trials to confirm these results are underway.",
author = "Feun, {L. G.} and R. Gonzalez and N. Savaraj and J. Hanlon and M. Collier and Robinson, {W. A.} and Clendeninn, {N. J.}",
year = "1991",
month = "12",
day = "1",
language = "English",
volume = "9",
pages = "464--467",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration

AU - Feun, L. G.

AU - Gonzalez, R.

AU - Savaraj, N.

AU - Hanlon, J.

AU - Collier, M.

AU - Robinson, W. A.

AU - Clendeninn, N. J.

PY - 1991/12/1

Y1 - 1991/12/1

N2 - A phase II trial of piritrexim (2,4-diamino-6[2,5-dimethoxybenzyl]-5-methyl pyrido-[2,3d] pyrimidine, 30IU74; PTX) was conducted for patients with metastatic malignant melanoma using an intermittent, low-dose oral administration schedule. PTX was administered at a starting dose of 25 mg orally three times per day for 5 days weekly for 3 weeks followed by 1 week of rest. Thirty-one patients were entered onto the study. Among 31 patients assessable for response, there were two complete responses (CRs) and five partial responses (PRs) for a response rate (CR plus PR) of 23% (95% confidence limit, 10% to 42%). Five responses occurred in soft tissue lesions, and two responses occurred in lung lesions. The initial dose schedule was well tolerated. The dose-limiting toxicity was myelosuppression. PTX administered in this schedule appears to be active against malignant melanoma. Further clinical trials to confirm these results are underway.

AB - A phase II trial of piritrexim (2,4-diamino-6[2,5-dimethoxybenzyl]-5-methyl pyrido-[2,3d] pyrimidine, 30IU74; PTX) was conducted for patients with metastatic malignant melanoma using an intermittent, low-dose oral administration schedule. PTX was administered at a starting dose of 25 mg orally three times per day for 5 days weekly for 3 weeks followed by 1 week of rest. Thirty-one patients were entered onto the study. Among 31 patients assessable for response, there were two complete responses (CRs) and five partial responses (PRs) for a response rate (CR plus PR) of 23% (95% confidence limit, 10% to 42%). Five responses occurred in soft tissue lesions, and two responses occurred in lung lesions. The initial dose schedule was well tolerated. The dose-limiting toxicity was myelosuppression. PTX administered in this schedule appears to be active against malignant melanoma. Further clinical trials to confirm these results are underway.

UR - http://www.scopus.com/inward/record.url?scp=0026065051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026065051&partnerID=8YFLogxK

M3 - Article

C2 - 1999717

AN - SCOPUS:0026065051

VL - 9

SP - 464

EP - 467

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -